Wednesday, July 8, 2026

pharma · Cholestatic liver disease · Cystic Fibrosis · PRQR

ProQR Therapeutics N.V

ProQR Therapeutics is a pharma organization headquartered in Leiden, NL. It trades on NYSE under ticker PRQR. Primary therapeutic focus areas include Cholestatic liver disease, Cystic Fibrosis, Autosomal Dominant Retinit

Leiden, NL HQ
2012 Founded
204 Employees
Public company Type
PRQR · NYSE Ticker
Company details
Status
Public
HQ
Leiden, NL
Founded
2012
Employees
204
Programs
6
Drugs
2
Patents
19
Clinical program

QR-010

Phase 2 · small molecule · Cystic Fibrosis

QR-010 for Cystic Fibrosis is a Phase 2 program (small_molecule) at ProQR Therapeutics N.V. with 2 ClinicalTrials.gov record(s).

← All ProQR Therapeutics N.V. projects Phase 2 small molecule completed

Internal code PQ-010-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ProQR Therapeutics N.V.
Phase
Phase 2
Modality
small_molecule
Indication
Cystic Fibrosis
Status
completed
Trials
2

Clinical trials